SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (50569)12/20/2018 3:57:27 PM
From: Art Bechhoefer  Read Replies (1) | Respond to of 52153
 
Yes, I follow FGEN. It remains grossly undervalued, especially when you consider recent highs. Even in a market fraught with uncertainty, it should not be difficult for FGEN to surpass $60 in the next six months, notwithstanding an overall market that may still be declining.

Art



To: scaram(o)uche who wrote (50569)12/20/2018 6:01:06 PM
From: Biomaven1 Recommendation

Recommended By
IRWIN JAMES FRANKEL

  Read Replies (5) | Respond to of 52153
 
>>Anybody here follow FGEN??

FGEN? I do recall buying some way back when. :)

I posted my thoughts on twitter - a very positive update today. Citi analyst is still an idiot, asking where safety data was.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News